From the Journals

Survey highlights interest in diet’s effects on RA


 

FROM ARTHRITIS CARE & RESEARCH

Nearly one-quarter of patients with long-standing rheumatoid arthritis who participated in a recent survey reported that their diets affect their RA symptoms.

Of 217 participants with a median disease duration of 17 years, 52 (24%) reported that certain foods either improve or worsen symptoms. Foods most commonly associated with improved symptoms were blueberries (11.1%), fish (10.9%), and spinach; foods most commonly associated with exacerbated symptoms were desserts (12.7%) and soda with sugar (12.4%, ), Sara K. Tedeschi, MD, of Brigham and Women’s Hospital, Boston, and her colleagues reported online in Arthritis Care & Research.

Povareshka/Thinkstock
Factors associated with these reports included younger age and improved symptoms resulting from sleep, warm room temperatures, and vitamin/mineral supplementation. Self-reported changes in symptoms did not differ based on medication use or disease activity scores, the investigators said (Arthritis Care Res. 2017. doi: 10.1002/acr.23225).

Participants came from a single-center RA registry (the Brigham RA Sequential Study, or BRASS) at a large academic center and were surveyed between May 2015 and December 2015. They were asked about the effects of 20 different foods that have been popularized as “inflammatory” or “anti-inflammatory” and about the effects of four lifestyle/environment factors. Most (83%) were women, and 58% were using a biologic disease-modifying antirheumatic drug.

The findings indicate that there is substantial patient interest in the effects of diet on RA symptoms and highlight the need for prospective studies on the topic, the investigators concluded. While strong conclusions cannot be drawn based on this survey, further study regarding a potential link between sugar consumption and inflammation is warranted.

Dr. Tedeschi’s work on this project was supported by the National Institutes of Health. The Brigham RA Sequential Study received funding from UCB, Crescendo Biosciences, Bristol-Myers Squibb, Amgen, and DxTerity.

Recommended Reading

FDA opens abbreviated approval pathway for interchangeable biosimilars
MDedge Rheumatology
Refractory RA patients respond well to peficitinib in phase II study
MDedge Rheumatology
Chikungunya arthritis symptoms reduced with immunomodulatory drugs
MDedge Rheumatology
Hydroxychloroquine dosing guidelines have little impact in clinical practice
MDedge Rheumatology
Perioperative infliximab does not increase serious infection risk
MDedge Rheumatology
ACR guidelines on HBV screening called inadequate
MDedge Rheumatology
Ultrasound guidance of early RA therapy doesn’t improve outcomes
MDedge Rheumatology
RA-BEAM trial shows that baricitinib improves RA symptoms, slows joint damage
MDedge Rheumatology
Methotrexate for RA: A 'fascinating drug’
MDedge Rheumatology
Pilot trial of first in kind biologic shows RA treatment potential
MDedge Rheumatology